Understanding FGN and ITG: The Basics
At a Glance
FGN and ITG are rare, usually non-amyloid kidney diseases in which abnormal antibody proteins collect in the kidney’s filters. A kidney biopsy, special stains, electron microscopy, and sometimes DNAJB9 testing or mass spectrometry help identify the deposits and distinguish these diseases from amyloidosis.
Being diagnosed with a rare kidney disease can feel overwhelming, especially when the name itself is a mouthful: Fibrillary Glomerulonephritis (FGN) or Immunotactoid Glomerulopathy (ITG). You might find that even some medical professionals are unfamiliar with these conditions because they are exceptionally rare [1].
In a typical setting, FGN accounts for only about 1% or less of all native kidney biopsies [2][3]. ITG is even rarer, representing a tiny fraction of kidney cases [4]. Because these conditions are so uncommon, it is normal to feel anxious or as if you are navigating uncharted territory. Your care will likely involve a specialist (nephrologist) and a pathologist who uses advanced technology to look deep inside your kidney tissue.
Breaking Down the Names
The names of these diseases describe what is happening at a microscopic level in your glomeruli—the tiny, delicate filters in your kidneys that clean your blood.
- Fibrillary Glomerulonephritis (FGN): This name comes from “fibrils,” which are tiny, solid, thread-like strands of protein. In FGN, these strands are usually tangled together randomly like a ball of yarn inside your kidney filters [5][6].
- Immunotactoid Glomerulopathy (ITG): This name refers to “microtubules.” Unlike the solid threads in FGN, these deposits are typically larger, hollow tubes that often line up in organized, parallel bundles [6][7].
- Glomerulopathy/Glomerulonephritis: These terms simply mean “disease or inflammation of the kidney filters” [6].
Why This is Usually Not Amyloidosis
You may hear the word “fibril” and worry about a better-known condition called amyloidosis. While both involve abnormal protein deposits, they are distinct diseases.
Doctors use a special orange-red dye called Congo red to screen for amyloidosis. Most cases of FGN and ITG do not pick up this stain, which is why they are often called “non-amyloid” diseases [6]. However, tests are rarely perfect in isolation. In the very rare cases where FGN does show some staining, specialized tests—like looking for a protein called DNAJB9—strongly support that it is FGN and not amyloidosis [8][9]. Pathologists look at all these clues together, sometimes requiring mass spectrometry for definitive answers if the case is unusual.
How These Conditions Damage the Kidneys
Your kidneys act as a sophisticated filtration system. In both FGN and ITG, abnormal proteins (mostly immunoglobulins, which are antibodies from your immune system) begin to clump together and get stuck in the filters [5].
As these protein clumps build up:
- They crowd the filters: The deposits physically take up space in the glomeruli, making it harder for the kidneys to filter waste [10].
- They cause “leaks”: The damage to the filter walls allows important proteins (like albumin) and sometimes blood to leak out of the blood and into your urine [10][11].
- They trigger inflammation: The presence of these abnormal proteins can cause the kidney to become inflamed, leading to scarring over time [6].
Who Typically Gets These Conditions?
While these diseases can affect anyone, they are most commonly diagnosed in adults around the age of 60 [11][12].
- FGN is often found more frequently in women than in men, though this can vary depending on the study [12][13]. It is sometimes associated with other conditions like hepatitis C or autoimmune diseases [14].
- ITG is so rare that it is harder to define a “typical” patient, but it is frequently linked to underlying blood conditions, such as chronic lymphocytic leukemia (CLL) or other issues where the body produces abnormal antibodies [15][11].
Symptoms and Presentation
Most patients discover they have FGN or ITG because of routine tests or new symptoms. Common signs include:
- Proteinuria: High levels of protein in the urine, which may make the urine look foamy or bubbly [10].
- Edema: Swelling, often in the legs, ankles, or around the eyes.
- Hematuria: Small amounts of blood in the urine, which may only be visible under a microscope [11].
- Hypertension: New or worsening high blood pressure [6].
- Reduced Kidney Function: A rise in creatinine levels or a drop in your eGFR (estimated glomerular filtration rate) [6].
Understanding your diagnosis starts with the pathology report from your kidney biopsy, where the doctor integrates light microscopy, stains, and electron microscopy to confirm whether you have FGN or ITG [7].
Common questions in this guide
What are FGN and ITG?
Are FGN and ITG the same as amyloidosis?
What symptoms can FGN or ITG cause?
How are FGN and ITG diagnosed?
Could FGN or ITG be linked to another health problem?
What should I ask about my kidney test results?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
About the conditions
How do FGN and ITG differ from amyloidosis?
Signs and symptoms
What symptoms are common with these kidney conditions?
Who is affected
Who is most often affected by these conditions?
Get notified when new evidence is published on Non-amyloid fibrillary glomerulopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Fibrillary Glomerulonephritis, DNAJB9, and the Unfolded Protein Response.
Andeen NK, Kung VL, Robertson J, et al.
Glomerular diseases 2022; (2(4)):164-175 doi:10.1159/000525542.
PMID: 36817290 - 2
DNA J homolog subfamily B member 9 and other advances in fibrillary glomerulonephritis.
Andeen NK, Avasare RS
Current opinion in nephrology and hypertension 2021; (30(3)):294-302 doi:10.1097/MNH.0000000000000706.
PMID: 33767057 - 3
[Fibrillary glomerulonephritis].
Dumas De La Roque C, Brocheriou I, Mirouse A, et al.
La Revue de medecine interne 2024; (45(11)):703-709 doi:10.1016/j.revmed.2024.05.005.
PMID: 38755072 - 4
End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.
Mallett A, Tang W, Hart G, et al.
American journal of nephrology 2015; (42(3)):177-84 doi:10.1159/000440815.
PMID: 26418732 - 5
Pathological diagnosis and differential considerations of renal diseases with organized deposits under an electron microscope: key points in diagnosis.
Mii A, Yamamoto Y, Ishikawa A, Shimizu A
Clinical and experimental nephrology 2026; (30(8)):1158-1168 doi:10.1007/s10157-026-02892-z.
PMID: 42149343 - 6
Glomerulopathies with Fibrillary Deposits.
Dzekova-Vidimliski P, Karanfilovski V, Nikolov IG, et al.
Prilozi (Makedonska akademija na naukite i umetnostite. Oddelenie za medicinski nauki) 2023; (44(2)):99-106 doi:10.2478/prilozi-2023-0030.
PMID: 37453107 - 7
[Glomerulopathies with organized monoclonal immunoglobulin deposits].
Touchard G, Bridoux F, Goujon JM
Nephrologie & therapeutique 2016; (12(1)):57-65.
PMID: 26810049 - 8
Congophilic Fibrillary Glomerulonephritis: A Case Series.
Alexander MP, Dasari S, Vrana JA, et al.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2018; (72(3)):325-336 doi:10.1053/j.ajkd.2018.03.017.
PMID: 29866458 - 9
DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.
Nasr SH, Vrana JA, Dasari S, et al.
Kidney international reports 2018; (3(1)):56-64 doi:10.1016/j.ekir.2017.07.017.
PMID: 29340314 - 10
DNAJB9 Fibrillary Glomerulonephritis With Membranous-Like Pattern: A Case-Based Literature Review.
Sabanis N, Liaveri P, Geladari V, et al.
Cureus 2023; (15(10)):e47862 doi:10.7759/cureus.47862.
PMID: 37899889 - 11
Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study.
Cohen AWS, Vilayur E
Internal medicine journal 2023; (53(10)):1837-1845 doi:10.1111/imj.15959.
PMID: 36305476 - 12
Fibrillary Glomerulonephritis: Clinicopathologic Features and Atypical Cases from a Multi-Institutional Cohort.
Andeen NK, Troxell ML, Riazy M, et al.
Clinical journal of the American Society of Nephrology : CJASN 2019; (14(12)):1741-1750 doi:10.2215/CJN.03870319.
PMID: 31685544 - 13
Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from a multi-institutional cohort.
Patrick J, Charles-Rudwick M, Quinn C, et al.
Clinical kidney journal 2025; (18(6)):sfaf166 doi:10.1093/ckj/sfaf166.
PMID: 40599627 - 14
Clinical Features and Outcomes of a Racially Diverse Population with Fibrillary Glomerulonephritis.
Payan Schober F, Jobson MA, Poulton CJ, et al.
American journal of nephrology 2017; (45(3)):248-256 doi:10.1159/000455390.
PMID: 28161700 - 15
[Latest updates on immunotactoid glomerulopathy and fibrillary glomerulonephritis].
Lafargue MC, Cohen C
Bulletin du cancer 2024; (111(7-8)):741-747 doi:10.1016/j.bulcan.2022.12.014.
PMID: 36803980
This page is for informational purposes only and does not constitute medical advice. Your nephrologist and renal pathologist should interpret your biopsy, DNAJB9 results, and kidney tests and advise you about next steps.